Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) Return on Sales (2016 - 2025)

Vanda Pharmaceuticals' Return on Sales history spans 16 years, with the latest figure at 2.47% for Q4 2025.

  • For Q4 2025, Return on Sales fell 238.0% year-over-year to 2.47%; the TTM value through Dec 2025 reached 1.02%, down 93.0%, while the annual FY2025 figure was 1.02%, 93.0% down from the prior year.
  • Return on Sales for Q4 2025 was 2.47% at Vanda Pharmaceuticals, down from 0.4% in the prior quarter.
  • Across five years, Return on Sales topped out at 0.14% in Q2 2021 and bottomed at 2.47% in Q4 2025.
  • The 5-year median for Return on Sales is 0.02% (2023), against an average of 0.19%.
  • The largest annual shift saw Return on Sales increased 16bps in 2023 before it plummeted -238bps in 2025.
  • A 5-year view of Return on Sales shows it stood at 0.1% in 2021, then grew by 2bps to 0.11% in 2022, then crashed by -150bps to 0.05% in 2023, then tumbled by -74bps to 0.09% in 2024, then tumbled by -2572bps to 2.47% in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Return on Sales are 2.47% (Q4 2025), 0.4% (Q3 2025), and 0.52% (Q2 2025).